These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 8558934)
1. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. Maslak PG; Weiss MA; Berman E; Yao TJ; Tyson D; Golde DW; Scheinberg DA Leukemia; 1996 Jan; 10(1):32-9. PubMed ID: 8558934 [TBL] [Abstract][Full Text] [Related]
2. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report. Hsu HC; Chiu CF; Tan TD; Chau WK; Tseng CS; Ho CH Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov; 56(5):305-11. PubMed ID: 8605644 [TBL] [Abstract][Full Text] [Related]
3. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia. Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264 [TBL] [Abstract][Full Text] [Related]
4. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346 [TBL] [Abstract][Full Text] [Related]
5. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia. Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968 [TBL] [Abstract][Full Text] [Related]
6. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study]. Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688 [TBL] [Abstract][Full Text] [Related]
7. Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia. Baek JH; Sohn SK; Kim DH; Kim JG; Yang DH; Kim YK; Lee JJ; Kim HJ Acta Haematol; 2007; 117(2):109-14. PubMed ID: 17135724 [TBL] [Abstract][Full Text] [Related]
8. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370 [TBL] [Abstract][Full Text] [Related]
9. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120 [TBL] [Abstract][Full Text] [Related]
10. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol. Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387 [TBL] [Abstract][Full Text] [Related]
11. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia. He XY; Pohlman B; Lichtin A; Rybicki L; Kalaycio M Leukemia; 2003 Jun; 17(6):1078-84. PubMed ID: 12764371 [TBL] [Abstract][Full Text] [Related]
12. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125 [TBL] [Abstract][Full Text] [Related]
13. Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission. Kantarjian HM; Estey E; O'Brien S; Anaissie E; Beran M; Pierce S; Robertson L; Keating MJ Cancer; 1993 Nov; 72(10):2950-5. PubMed ID: 7693325 [TBL] [Abstract][Full Text] [Related]
14. GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly. Pierri I; Clavio M; Beltrami G; Cavaliere M; Lanza L; Miglino M; Canepa L; Pietrasanta D; Ballerini F; Quintino S; Gatto S; Celesti L; Carrara P; Varese P; Gobbi M J Exp Clin Cancer Res; 1999 Mar; 18(1):55-60. PubMed ID: 10374678 [TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Archimbaud E; Fenaux P; Reiffers J; Cordonnier C; Leblond V; Travade P; Troussard X; Tilly H; Auzanneau G; Marie JP Leukemia; 1993 Mar; 7(3):372-7. PubMed ID: 8445942 [TBL] [Abstract][Full Text] [Related]
16. Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups. Bassan R; Chiodini B; Lerede T; Giussani U; Oldani E; Buelli M; Rossi A; Viero P; Rambaldi A; Barbui T Hematol J; 2002; 3(4):193-200. PubMed ID: 12189565 [TBL] [Abstract][Full Text] [Related]
17. Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. Schaich M; Illmer T; Aulitzky W; Bodenstein H; Clemens M; Neubauer A; Repp R; Schäkel U; Soucek S; Wandt H; Ehninger G; Haematologica; 2002 Aug; 87(8):808-15. PubMed ID: 12161356 [TBL] [Abstract][Full Text] [Related]
18. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. Löwenberg B; van Putten W; Theobald M; Gmür J; Verdonck L; Sonneveld P; Fey M; Schouten H; de Greef G; Ferrant A; Kovacsovics T; Gratwohl A; Daenen S; Huijgens P; Boogaerts M; ; N Engl J Med; 2003 Aug; 349(8):743-52. PubMed ID: 12930926 [TBL] [Abstract][Full Text] [Related]
19. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852 [TBL] [Abstract][Full Text] [Related]
20. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]